TVTX
Travere Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +4.3% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.17M | $68.91M | n/a | n/a |
| Q2 2026 | 114 | +17 | 68.21M | $3.64B | +21 | −4 |
| Q1 2026 | 100 | -5 | 69.82M | $2.07B | +9 | −14 |
| Q4 2025 | 104 | +1 | 74.66M | $2.85B | +1 | n/a |
| Q3 2025 | 21 | +1 | 36.01M | $860.71M | +2 | −2 |
| Q2 2025 | 18 | +1 | 30.33M | $448.83M | +2 | −1 |
| Q1 2025 | 14 | 0 | 16.78M | $300.70M | n/a | n/a |
| Q4 2024 | 14 | +1 | 16.09M | $280.22M | +2 | −1 |
| Q3 2024 | 12 | -1 | 7.80M | $109.09M | +1 | −2 |
| Q2 2024 | 13 | n/a | 10.32M | $84.85M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 3.65M | -3.2% | $65.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 2.70M | +12.2% | $48.43M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Viking Global Investors ✦ | 2.60M | -10.3% | $46.63M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 2.18M | +479.9% | $39.15M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.98M | +7.3% | $35.43M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 1.71M | -24.8% | $30.71M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 768.79K | +10.9% | $13.78M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 8 | Citadel Advisors ✦ | 524.34K | -9.5% | $9.40M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 9 | AQR Capital Management ✦ | 399.31K | -5.8% | $7.16M | 0.0% | ▼ Trim | 4 | SEC ↗ ×5 |
| 10 | Norges Bank ✦ (passive) | 71.00K | 0.0% | $1.27M | 0.0% | Held | 4 | SEC ↗ |
| 11 | Millennium Management ✦ | 59.83K | -90.4% | $1.07M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 53.31K | +34.6% | $956,000 | 0.0% | ▲ Add | 4 | SEC ↗ |
| 13 | Fisher Asset Management ✦ | 43.18K | 0.0% | $773,821 | 0.0% | Held | 4 | SEC ↗ |
| 14 | Wellington Management ✦ | 33.17K | -1.0% | $594,407 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 121.20K shares, $3,600 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 78.40K sh · $4.31M
Officer, Director · 37.27K sh · $2.02M
Officer, Director · 128.06K sh · $6.78M
Officer · 8.28K sh · $538,917
Officer, Director · 101.69K sh · $6.57M
Officer, Director · 6.80K sh · $441,795
Officer, Director · 99.72K sh · $6.31M
Officer · 79.11K sh · $5.04M
Officer · 93.60K sh · $5.92M
Officer, Director · 96.12K sh · $6.12M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology